Tenon Medical (TNON) updates terms on $5.16M 2026 notes
Rhea-AI Filing Summary
Tenon Medical, Inc. (TNON) filed an amended current report to correct details of a recently issued convertible note financing. The amendment clarifies that the company issued an aggregate principal amount of $5.16 million of 20% Original Issue Discount Senior Convertible Promissory Notes in a private placement, generating approximately $4.3 million in gross proceeds. The notes mature on September 11, 2026, with an option for the company to extend to December 11, 2026, and are convertible after six months at a price equal to 80% of the three-day VWAP, with a corrected floor price of $0.1567. If the maturity is extended, principal increases by 5%; any prepayment is at 102.5% of principal, and 15% of net proceeds from future securities financings must be used to prepay the notes. Tenon agreed to pay its placement agent a 7% cash fee plus $65,000 in expenses. The offering relied on Section 4(a)(2) and Regulation D/Rule 506(b) exemptions from registration.
Positive
- None.
Negative
- None.
8-K Event Classification
4 items: 1.01, 3.02, 8.01, 9.01
4 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Aggregate principal amount of Notes: $5.16 million
Aggregate gross proceeds: $4.3 million
Original Issue Discount: 20%
+5 more
8 metrics
Aggregate principal amount of Notes
$5.16 million
20% Original Issue Discount Senior Convertible Promissory Notes issued in private placement
Aggregate gross proceeds
$4.3 million
Gross proceeds from the private placement before fees and expenses
Original Issue Discount
20%
Discount on Senior Convertible Promissory Notes
Conversion price formula
80% of VWAP
80% of VWAP for the three Trading Days immediately prior to conversion
Floor conversion price
$0.1567
Corrected floor price in form of Note (Exhibit 4.1)
Prepayment premium
102.5%
Any prepayment of the Notes is at 102.5% of principal
Mandatory prepayment from financings
15%
Portion of net proceeds from any securities financing used to prepay Notes
Placement agent fee
7%
Cash fee as a percentage of aggregate gross proceeds, plus $65,000 expenses
Key Terms
Original Issue Discount, Senior Convertible Promissory Notes, VWAP, Regulation D, +2 more
6 terms
Original Issue Discount financial
"20% Original Issue Discount Senior Convertible Promissory Notes"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
Senior Convertible Promissory Notes financial
"aggregate principal amount of $5.16 million 20% Original Issue Discount Senior Convertible Promissory Notes"
A senior convertible promissory note is a formal IOU where a company borrows money and promises to repay it, with this loan getting first priority for repayment if the company runs into trouble. The note also gives the lender the option to swap the debt for company shares, like turning an IOU into ownership, which can dilute existing shareholders. Investors care because it affects a company’s cash needs, its risk profile (higher priority reduces lender risk), and the potential for future share dilution if conversion occurs.
VWAP financial
"conversion price equal to 80% of the VWAP for the three (3) Trading Days"
VWAP, or Volume-Weighted Average Price, is a way to find the average price of a stock throughout the trading day, giving more importance to times when more shares are traded. It helps traders see the typical price and decide whether a stock is expensive or cheap compared to its average, similar to finding the average speed during a trip by giving more weight to times when you traveled faster or slower.
Regulation D regulatory
"exemption from the registration requirements under the Securities Act available under Section 4(a)(2) and/or Regulation D"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
Section 4(a)(2) regulatory
"reliance on the exemption from registration provided by Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Regulation 506(b) regulatory
"reliance on the exemption from registration provided by Section 4(a)(2) and Regulation 506(b)"
FAQ
What financing did Tenon Medical (TNON) correct and describe in this 8-K/A?
Tenon Medical corrected and described a private placement of $5.16 million aggregate principal amount of 20% Original Issue Discount Senior Convertible Promissory Notes, which generated approximately $4.3 million in gross proceeds before placement agent fees and expenses.
What are the maturity terms of Tenon Medical (TNON)'s new notes?
The notes mature on September 11, 2026. Tenon Medical may extend the maturity date to December 11, 2026, in which case the outstanding principal amount of the notes will be increased by 5% as specified in the agreement.
How are Tenon Medical (TNON)'s notes convertible into common stock?
Following the six-month anniversary of issuance, the notes are convertible into Tenon’s common stock at a price equal to 80% of the VWAP for the three trading days immediately prior to conversion, subject to adjustments and a corrected floor conversion price of $0.1567.
What prepayment provisions apply to Tenon Medical (TNON)'s notes?
Any voluntary prepayment must be made at 102.5% of the principal amount prepaid. In addition, Tenon is required to prepay the notes in an amount equal to 15% of the net proceeds it receives from any securities financing transaction.
What compensation does the placement agent receive in Tenon Medical (TNON)'s offering?
Tenon Medical engaged WallachBeth Capital LLC as placement agent. The company agreed to pay a cash fee equal to 7% of the aggregate gross proceeds raised in the offering and to reimburse the placement agent for $65,000 of its expenses.
Under what securities law exemptions did Tenon Medical (TNON) issue the notes?
Tenon Medical issued and sold the notes in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D, including Rule 506(b), because the transaction did not involve a public offering of securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
